Evidence map›Paper›PMID 42646336›Full record

ReviewMetabolites2026

Machine Learning-Integrated Metabolomics for Precision Pharmacotherapy: Advances, Challenges, and Clinical Translation.

Pan Li, Jing Mao, Xianglin Hu, Yujiao Hu, Xiaoke Zhang, Qian Zheng, Xiaoying Hou, Yuchen Liu, Min Huang

Abstract readReview
In one paragraph

Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pan LiCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.ORCID 0000-0002-2819-4439
Jing MaoDepartment of Pharmacy, Shenzhen Children's Hospital, Shenzhen 518026, China.
Xianglin HuCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.ORCID 0009-0002-0394-4229
Yujiao HuCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.ORCID 0009-0000-9072-8393
Xiaoke ZhangCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.
Qian ZhengHubei Key Laboratory of Cognitive and Affective Disorders, Jianghan University, Wuhan 430056, China.
Xiaoying HouCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.ORCID 0000-0002-9201-3970
Yuchen LiuCancer Institute, School of Medicine, Jianghan University, Wuhan 430056, China.ORCID 0000-0001-7775-2671
Min HuangInstitute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Funding

National Natural Science Foundation of China 82504919Natural Science Foundation of Hubei Province 2024AFB941Research Fund of Jianghan University 2021jczx-002
6 · The paper itself

Abstract

Machine learning (ML) integrated with metabolomics has emerged as a promising strategy to advance precision pharmacotherapy, enabling data-driven prediction of drug response. This review provides an overview of commonly applied ML methodologies in metabolomics-based pharmacological studies, including supervised models (Random Forest, Extreme Gradient Boosting, Support Vector Machine, Logistic Regression, K-Nearest Neighbors), unsupervised models (K-Means Clustering, Principal Component Analysis), and deep learning approaches. We summarize recent progress in the application of metabolomics-driven ML to personalized medication, with a focus on drug dosage optimization, therapeutic efficacy prediction, and adverse drug reaction assessment. Despite these advances, significant challenges remain, including limited explainability, insufficient prospective clinical validation, lack of standardization and reproducibility, and data dimensionality and quality issues. Addressing these issues will be essential for the clinical translation of ML-metabolomics integration. Looking ahead, continued methodological innovation, large-scale multi-center prospective validation, and integration with other omics platforms will be key to unlocking the full potential of metabolomics combined with ML in precision healthcare.

Indexed as

adverse drug reactionsdrug response predictionmachine learningmetabolomicsprecision pharmacotherapy

Identifiers

PMID42646336
PMCPMC13515566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.